Miccil

Bumetanide

Method of action: Diuretic

Treatment option: Glomerulonephritis, Congestive Heart Failure, Nephrotic Syndrome, Edema, Renal Dysfunction, Renal Failure, Heart Failure, Toxemia Of Pregnancy, Cirrhosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miccil

This introductory section provides essential facts regarding the identity and general utility of the medication Miccil, containing the active ingredient Bumetanide.

Quick Facts

Property	Description
Active ingredient	Bumetanide
Form	Tablet, Parenteral preparation (Injection)
Pharmacological class	Loop Diuretic (High-ceiling diuretic)
Common use	Management of excess fluid and salt retention
Origin	Synthetic compound (Sulfamyl derivative)

What Type of Medicine is Miccil (Bumetanide)?

Miccil is a potent, prescription-only medication classified as a Loop diuretic, or High-ceiling diuretic, due to its significant and rapid capability to increase fluid excretion. Its active ingredient is the synthetic chemical compound Bumetanide, which belongs to the Sulfamyl derivative group. The medication is considered an essential medicine, signifying its established utility within global healthcare systems. The classification as a Loop diuretic establishes its function as a powerful tool in managing fluid volume, clinically recognized for its rapid onset of action compared to many other diuretics. This high potency ensures prompt management of fluid imbalances when substantial diuresis (urine output) is medically necessary.

What is Miccil Made Of and What Forms Does it Come In?

Miccil is a single-entity product containing only the active ingredient Bumetanide, formulated with necessary pharmaceutical excipients suitable for its method of delivery. The medication is available in two primary pharmaceutical preparations: the tablet for oral use and a parenteral preparation designed for intravenous (IV) or intramuscular (IM) injection. Bumetanide functions to rid the body of excess salt and water. This mechanism confirms the medication's core goal is the expulsion of accumulated fluid. The availability of both forms is crucial for therapeutic flexibility; the oral tablet supports routine management needs, whereas the injectable form is reserved for situations requiring immediate and controlled therapeutic effects.

What is the General Purpose of Taking Miccil?

The core utility of Miccil is to rapidly and effectively facilitate the removal of excess accumulated fluid and salt from the body by modulating renal processes. This action is achieved by interfering with the kidney's ability to reabsorb salts, thereby causing water to leave the body via urine. The general benefit is the effective reduction of overall fluid volume in the tissues and circulation, such as in instances of fluid retention causing noticeable swelling. Essentially, the medication serves to restore a safer, more balanced fluid level, which helps to alleviate physical conditions associated with unwanted fluid retention.

Regulatory References

What side effects are possible with Miccil?

Possible Side Effects and Safety Information

The safety profile of Miccil (Bumetanide) is documented in official prescribing information and is defined by the medicine's potent action as a loop diuretic. Regulatory safety data categorizes potential effects based on frequency and the physiological systems involved.

Adverse Reaction Categories

Adverse reactions are classified according to incidence. Common effects, reported in official documentation, primarily involve Metabolism and Nutrition Disorders, such as disturbances in fluid and electrolyte balance, including low blood levels of potassium (Hypokalemia) and sodium (Hyponatremia), as well as dehydration, headache, and dizziness. Uncommon reactions may include hearing disorders (Ototoxicity), rash, and abdominal discomfort. Rare events, such as certain blood disorders like Thrombocytopenia (low platelets), are also officially documented.

Classification	Examples of Reactions (System-Organ Class)
Common	Electrolyte imbalance, Headache, Dizziness
Uncommon	Ototoxicity, Rash, Abdominal pain
Rare	Blood dyscrasias (e.g., Thrombocytopenia)

Serious Adverse Reactions and Restrictions

Specific serious adverse reactions are highlighted in regulatory safety documents. These include the potential for Hepatic Encephalopathy, a severe neurological complication that is a particular risk for individuals with pre-existing severe liver impairment. The medication is also formally contraindicated by regulatory agencies in the presence of specific conditions, such as Anuria (absence of urine production), Hepatic Coma or pre-comatose states, and known Hypersensitivity to the drug or sulfonamide derivatives. The risk of Ototoxicity is increased when the medication is administered at high doses or rapidly, or in individuals with renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Miccil (Bumetanide) is documented in regulatory labeling as primarily causing a crisis of profound water loss and excessive diuresis. This leads to severe dehydration and a critical reduction in blood volume (hypovolemia). The clinical signs of overdose stem from severe electrolyte depletion (such as hypokalemia or hyponatremia) and may include symptoms like weakness, mental confusion, vomiting, lethargy, and muscle cramps.

Severe Outcomes and Monitoring

The most severe documented consequences are circulatory collapse and the risk of vascular thrombosis and embolism. In patients with pre-existing hepatic cirrhosis and ascites, rapid electrolyte changes may precipitate hepatic encephalopathy and coma. This risk of thrombosis and embolism is particularly noted for elderly patients.

Emergency Action Requirements

Regulators mandate that immediate medical attention must be sought for any manifestations of severe volume depletion or life-threatening symptoms. Careful medical supervision is required in all suspected cases of overdose. Management is strictly symptomatic and supportive, as no specific antidote is documented in the official labels. Supportive measures described include procedures to restore blood volume, maintain blood pressure, and correct electrolyte disturbances. Hospital monitoring of clinical status and electrolyte balance is required, especially for high-risk patient groups.

Therapeutic Uses of Miccil

Reducing Fluid Overload in Heart and Systemic Conditions

Miccil is commonly used in conditions characterized by periods of heightened symptoms related to fluid accumulation (edema) and congestion, particularly when stemming from a systemic imbalance, such as in Congestive Heart Failure. The medication is applied in addressing pronounced symptoms like swelling in the legs and ankles and the shortness of breath (dyspnea) caused by fluid backing up into the lungs. The medication supports fluid management, which contributes to easing the overall symptom load and offers symptomatic relief during these distressing manifestations.

Managing Edema Associated with Liver and Kidney Disease

The medication is also relevant in conditions involving nephrotic syndrome or fluid accumulation like ascites secondary to liver disease. It helps address symptom patterns that cluster into noticeable interference with daily stability. Miccil provides support that contributes to improved comfort during periods of heightened symptoms by supporting the management of excess water and salt.

Support for Severe and Refractory Volume Accumulation

Miccil is often applied during phases when the patient experiences heightened discomfort due to fluid retention that is either acute (e.g., severe pulmonary edema) or refractory (unresponsive to standard management). Used in situations requiring temporary assistance in symptom stabilization, the medication may assist with achieving symptomatic relief, which helps patients cope more steadily with difficult episodes.

Quick Fact: Symptomatic Support for Fluid Overload

Benefit Focus	Symptom Managed	Context
Symptomatic Support	Peripheral Edema (Swelling)	Chronic management of fluid retention
Dyspnea Management	Dyspnea (Shortness of Breath)	Acute volume overload in the lungs
Comfort Improvement	Ascites (Abdominal Fluid)	Fluid accumulation secondary to liver disease

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Miccil (Bumetanide)

The eligibility for using Miccil is strictly defined by regulatory authorities based on population age, existing medical conditions, and physiological state.

Populations for Whom Use is Prohibited (Contraindicated)

Miccil must not be used in patients with Anuria (inability to form urine), Hepatic Coma or states leading to hepatic encephalopathy, or Severe Electrolyte Depletion until the condition is corrected. Use is also prohibited for individuals with a known Hypersensitivity to Bumetanide or any components of the tablet or injection.

Age and Physiological Restrictions

Population Group	Regulatory Eligibility Status
Adults (18+ years)	Established: Approved population for labeled indications.
Pediatric Population	Not Recommended: Safety and efficacy are not established by regulatory studies.
Pregnancy	Restricted: Use is not recommended unless the benefit clearly outweighs the potential risk.
Breastfeeding	Not Recommended: Breastfeeding should be discontinued during treatment.

Conditional Use and Caution

Patients with Severe Renal Impairment or Severe Hepatic Impairment require caution and close monitoring during use. Treatment must be discontinued if a marked increase in Blood Urea Nitrogen (BUN) or creatinine occurs. Older adults also require cautious dose selection due to reduced clearance.

What should I know about interactions with other medicines?

The official regulatory profile for Miccil (Bumetanide) documents several clinically significant interaction patterns based on pharmacodynamic and pharmacokinetic mechanisms. The primary interaction risk involves the additive effects of co-administered medicines.

Additive Toxicities and Enhanced Effects

Concurrent use with other ototoxic agents, such as aminoglycoside antibiotics, or nephrotoxic agents is officially associated with an increased risk of organ toxicity. Administration alongside other antihypertensive agents can potentiate the risk of postural hypotension. The risk of profound hypokalemia is heightened when Miccil is combined with other hypokalemia-inducing agents, including corticosteroids or Digitalis, particularly in patients with congestive heart failure.

Drug Exposure and Efficacy Alterations

Interaction effects on drug exposure are documented in regulatory sources. Lithium serum concentrations are increased due to Bumetanide reducing its renal clearance. Similarly, Probenecid reduces the renal clearance of Bumetanide itself, which diminishes the natriuretic (salt-excreting) response. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin, diminish the intended diuretic and antihypertensive efficacy. Efficacy is also reduced by high-sodium products, such as specific soluble painkillers or antacids, due to the sodium content counteracting the drug's action.

Population-Specific Considerations

The label notes population-specific interaction considerations. In neonates, there is a documented risk of bilirubin displacement from protein-binding sites, which is a concern for kernicterus in critically ill or jaundiced infants. For geriatric patients, total bumetanide clearance is lower, which increases the risk of toxic reactions.

Mechanism of Action

Highly Specific Blockade of Renal Salt Transport

Miccil (Bumetanide) acts by targeting the Na-K-2Cl cotransporter type 2 ( NKCC2), a high-capacity ion pump situated on the luminal membrane of the cells in the thick ascending limb of the renal Loop of Henle. The molecule functions as a competitive inhibitor at this site, which structurally halts the simultaneous movement and reabsorption of sodium ( Na^+), potassium ( K^+), and chloride ( Cl^-) ions from the tubular fluid back into the circulation. This molecular blockade is the initial step that determines the drug's physiological action.

Driving Force Alteration and Systemic Fluid Excretion

By retaining a substantial quantity of salt within the kidney tubules, the drug alters the osmotic driving force, which prevents water reabsorption and causes it to remain in the forming urine. This cascade produces significant Natriuresis (salt loss) and subsequent Diuresis (water loss), thereby modulating the balance of total extracellular fluid volume. The mechanism also secondarily affects the excretion of divalent cations like magnesium and calcium.

Functional Limits of the Mechanistic Cascade

The efficacy of NKCC2 blockade is dependent on drug delivery, which requires active tubular secretion in the proximal tubule. Reduced delivery to the target membrane functionally constrains the inhibitory mechanism, resulting in a physiologically reduced extent of diuresis.

Dosage and Administration Information

Miccil, containing the active ingredient Bumetanide, is administered primarily by the oral route using tablets, though a parenteral preparation allows for both intravenous (IV) or intramuscular (IM) injection when oral absorption is compromised. The injection form is reserved for limited circumstances and should be transitioned to the oral tablet as soon as possible. The medication is typically taken once daily, and may be taken with or without food. To avoid disruption of sleep, the dose is typically taken in the morning or early evening.

The standard starting oral dose for an adult is generally 0.5 mg to 2 mg. If the diuretic response is inadequate, the dose may be repeated at 4-5 hour intervals for up to two additional doses, with the maximum recommended total daily dose not exceeding 10 mg for intermittent use.

Dosage adjustments are specifically outlined for certain patient populations. Therapy should be initiated at the low end of the dosing range, often 0.5 mg, for older adults due to documented differences in drug clearance. In cases of significant liver impairment, the dose must be strictly kept to a minimum effective level. If a patient with progressive renal disease develops a marked increase in laboratory values or experiences low urine output (oliguria), the discontinuation of treatment is indicated.

Recent Clinical Evidence

Miccil is an international brand name for the generic drug bumetanide, which belongs to a class of medicines called loop diuretics, or "water pills."

The information below is a summary of the clinical evidence regarding the use of bumetanide.

Efficacy in Edematous Conditions

Bumetanide is approved for managing various edematous conditions, or fluid retention, caused by underlying conditions such as congestive heart failure, liver disease, or renal disease (including nephrotic syndrome).

Primary Clinical Use: Studies have established bumetanide's role in promoting the excretion of salt and water by the kidneys. This action helps reduce swelling and fluid overload in patients with these conditions.
Refractory Edema: Research supports its use in cases of severe edema that have not responded adequately to other diuretics.
Administration: The drug is available in both oral (tablet) and injectable forms, with rapid absorption noted after administration.

Safety and Adverse Events Profile

Clinical trials and post-market surveillance have established a known safety profile for bumetanide, emphasizing the need for monitoring due to its potent diuretic action.

Fluid and Electrolyte Imbalance: Because of its mechanism, the most frequently observed effects in studies involve the depletion of fluid and electrolytes. Common reported events include hypokalemia (low potassium), hyponatremia (low sodium), and hypochloremia (low chloride).
Common Adverse Events (Reported Incidence > 1%):
- Hyperuricemia (elevated uric acid)
- Azotemia (elevated nitrogen compounds in the blood)
- Dizziness and muscle cramps
Serious Risks: Although rare, studies and regulatory warnings highlight the potential for ototoxicity (hearing impairment), which is usually transient, and the risk of precipitating hepatic encephalopathy in patients with pre-existing liver disease (cirrhosis).

Off-Label Investigation and Contraindications

Bumetanide is sometimes investigated for uses beyond its primary approval. For example, it has been explored in clinical trials related to conditions like Alzheimer's disease and autism spectrum disorder based on preclinical data, though these are not approved indications.

Clinical trials typically exclude participants with conditions like anuria (absence of urine production), hepatic coma, or severe **electrolyte depletion).

Key Studies & References NICE Guideline NG200: Management of Condition Y (Updated 2024)

Frequently Asked Questions (FAQ)

Common questions about Miccil (FAQ)

Q: How long does it usually take to feel the general effects of Miccil?

According to official product information, when Miccil is taken orally, the onset of diuresis (increased urination) typically begins relatively quickly, occurring within 30 to 60 minutes. The maximum change in fluid excretion is generally observed between one and two hours after administration.

Q: Does Miccil cause changes in appetite or weight?

Official safety documents indicate that changes in appetite and weight are potential adverse reactions. Specifically, loss of appetite is noted as a symptom associated with an excessive dose. Unexplained weight loss and weight gain are also listed in safety monitoring reports for the medication.

Q: What happens if I accidentally take Miccil too close to another dose?

The administration intervals described in regulatory guidance are intended to prevent excessive dosing. Excessive doses or too frequent administration can lead to profound loss of water and electrolytes. Guidance for a missed dose advises against taking a double dose to mitigate this risk.

Q: How long after stopping Miccil do the medicine's effects typically wear off?

The official pharmacology information states that the medicine's primary effect—the increased excretion of fluid—is generally complete within four hours of taking a typical oral dose. This duration may extend slightly to about six hours with higher doses.

Q: If I miss a day of taking Miccil, will it affect the overall process?

Official guidance addresses missed doses to help maintain the prescribed dosing schedule, which is necessary to manage fluid volume. The goal is to regulate fluid levels over time, and a healthcare professional should be consulted regarding how best to maintain this schedule.

Q: What kind of specialist typically prescribes Miccil?

Miccil is officially indicated for the management of fluid retention related to specific conditions, including congestive heart failure, liver disease, and kidney disease. Therefore, the drug is typically used by specialists focusing on these areas, such as cardiologists, nephrologists, or hepatologists.

Q: Can Miccil be taken by people who are sensitive to certain dyes or fillers?

Official regulatory labeling includes a complete list of all inactive ingredients used in the product formulation. This list details components such as lactose, corn starch, and specific dye systems for each tablet strength, and is available for review by patients and prescribers.

Q: Why do some people say Miccil didn't work for them?

Official documents describe factors that can influence the drug's intended action. Its efficacy is constrained by proper delivery to the kidney, which may be reduced in some cases. Furthermore, studies note that combining Miccil with certain other medications, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), can diminish its diuretic effect.

Q: Is it possible for Miccil to cause changes in blood test results?

Official safety information explicitly indicates that this medication can cause changes in laboratory values. These changes may affect measures like electrolytes (e.g., sodium and potassium), uric acid, creatinine, and Blood Urea Nitrogen (BUN), which necessitates monitoring by a healthcare professional.

Q: Is there a generic version of Miccil available?

Yes, the generic name for Miccil is bumetanide. According to official regulatory records, the tablet formulation is available as an approved generic equivalent.

Q: How should I keep track of side effects while taking Miccil?

Official information states that careful medical supervision is required due to the drug’s potent effect. This process often includes the monitoring and reporting of any symptoms of adverse effects, particularly those suggesting electrolyte imbalance, by the patient to their healthcare team.

Q: Why is Miccil sometimes given instead of other treatments?

Regulatory documents indicate that the medication's high potency makes it an option for patients experiencing fluid retention that has been unresponsive or refractory to other diuretics. It is also officially noted for being a particularly powerful tool compared to other drugs in the same class.

How should Miccil be stored and disposed of?

How to Store and Dispose of Miccil?

The official storage conditions for Miccil (Bumetanide) are designed to maintain the medication's stability and efficacy.

Requirement	Specification
Storage Temperature	Store at 20^circ to 25 C (68^circ to 77 F) (Controlled Room Temperature).
Handling & Protection	Keep from freezing and protect the product from light.
Container Rule	Dispense in a tight, light-resistant container.

It is a mandatory regulatory requirement to KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

Regarding disposal, unused or expired Miccil should not be thrown away via household waste or wastewater. Consult a healthcare professional or local waste disposal service for instructions to discard the medicine in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.